NCT05605782View on ClinicalTrials.gov

A Post-Authorization, Long-term Study of Ozanimod Real-world Safety

Active, not recruitingOBSERVATIONAL
Enrollment

9,000

Participants

Timeline

Start Date

September 2, 2021

Primary Completion Date

July 26, 2033

Study Completion Date

July 26, 2033

Conditions
Multiple Sclerosis, Relapsing-Remitting
Trial Locations (1)

20814

Evidera, Bethesda

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05605782 - A Post-Authorization, Long-term Study of Ozanimod Real-world Safety | Biotech Hunter | Biotech Hunter